Absorption, Metabolism, and Excretion of [(14)C]-Tolebrutinib After Oral Administration in Humans, Contribution of the Metabolites to Pharmacological Activity

BACKGROUND AND OBJECTIVE: Tolebrutinib is a covalent inhibitor of Bruton’s tyrosine kinase, an enzyme expressed in B lymphocytes and myeloid cells including microglia, which are thought to be major drivers of inflammation in multiple sclerosis. This excretion balance and metabolism study evaluated t...

Descripción completa

Detalles Bibliográficos
Autores principales: Nicolas, Olivier, Moliner, Patricia, Soubayrol, Patrick, Vitse, Olivier, Roy, Sebastien, Cabanis, Marie-José, Turner, Tim, Klieber, Sylvie, Muccio, Stephane, Arabeyre, Catherine, Brun, Priscilla
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10480245/
https://www.ncbi.nlm.nih.gov/pubmed/37642857
http://dx.doi.org/10.1007/s40261-023-01296-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10480245/
https://www.ncbi.nlm.nih.gov/pubmed/37642857
http://dx.doi.org/10.1007/s40261-023-01296-1

Ejemplares similares